Further support for loss of endothelial BMP9/10 signaling is provided by the identification of pathogenic mutations in the GDF2 (BMP9) and, to a lesser extent, BMP10 genes in some PAH patients. This evidence concerns the gene BMP10 and pulmonary arterial hypertension.